Literature DB >> 12663445

The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein.

Eric Spierings1, Anthony G Brickner, Jennifer A Caldwell, Suzanne Zegveld, Nia Tatsis, Els Blokland, Jos Pool, Richard A Pierce, Sahana Mollah, Jeffrey Shabanowitz, Laurence C Eisenlohr, Peter van Veelen, Ferry Ossendorp, Donald F Hunt, Els Goulmy, Victor H Engelhard.   

Abstract

Minor histocompatibility (H) antigens crucially affect the outcome of human leukocyte antigen (HLA)-identical allogeneic stem cell transplantation (SCT). To understand the basis of alloimmune responses against minor H antigens, identification of minor H peptides and their antigenicity-determining mechanisms is essential. Here we report the identification of HA-3 and its encoding gene. The HA-3 peptide, VTEPGTAQY (HA-3T), is encoded by the lymphoid blast crisis (Lbc) oncogene. We thus show for the first time that a leukemia-associated oncogene can give rise to immunogenic T-cell epitopes that may have participated in antihost and antileukemic alloimmune responses. Genotypic analysis of HA-3- individuals revealed the allelic counterpart VMEPGTAQY (HA-3M). Despite the lack of T-cell recognition of HA-3- cells, the Thr-->Met substitution had only a modest effect on peptide binding to HLA-A1 and a minimal impact on recognition by T cells when added exogenously to target cells. This substitution did not influence transporter associated with antigen processing (TAP) transport, but, in contrast to the HA-3T peptide, HA-3M is destroyed by proteasome-mediated digestion. Thus, the immunogenicity of minor H antigens can result from proteasome-mediated destruction of the negative allelic peptide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663445     DOI: 10.1182/blood-2003-01-0260

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.

Authors:  Anthony G Brickner; Anne M Evans; Jeffrey K Mito; Suzanne M Xuereb; Xin Feng; Tetsuya Nishida; Liane Fairfull; Robert E Ferrell; Kenneth A Foon; Donald F Hunt; Jeffrey Shabanowitz; Victor H Engelhard; Stanley R Riddell; Edus H Warren
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

2.  Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing.

Authors:  Danijela Koppers-Lalic; Eric A J Reits; Maaike E Ressing; Andrea D Lipinska; Rupert Abele; Joachim Koch; Marisa Marcondes Rezende; Pieter Admiraal; Daphne van Leeuwen; Krystyna Bienkowska-Szewczyk; Thomas C Mettenleiter; Frans A M Rijsewijk; Robert Tampé; Jacques Neefjes; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-25       Impact factor: 11.205

3.  A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

Authors:  Björn de Rijke; Agnes van Horssen-Zoetbrood; Jeffrey M Beekman; Britt Otterud; Frans Maas; Rob Woestenenk; Michel Kester; Mark Leppert; Anton V Schattenberg; Theo de Witte; Elly van de Wiel-van Kemenade; Harry Dolstra
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

4.  Recognition of allo-peptide is governed by novel anchor imposition and limited variations in TCR contact residues.

Authors:  Corbett J A Reinbold; Subramaniam Malarkannan
Journal:  Mol Immunol       Date:  2007-11-05       Impact factor: 4.407

5.  The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.

Authors:  Victor H Engelhard
Journal:  Int J Mass Spectrom       Date:  2007-01-01       Impact factor: 1.986

6.  Identification of minor histocompatibility antigens based on the 1000 Genomes Project.

Authors:  Rimke Oostvogels; Henk M Lokhorst; Monique C Minnema; Maureen van Elk; Kelly van den Oudenalder; Eric Spierings; Tuna Mutis; Robbert M Spaapen
Journal:  Haematologica       Date:  2014-08-22       Impact factor: 9.941

7.  Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Willemijn Hobo; Kelly Broen; Walter J F M van der Velden; Annelies Greupink-Draaisma; Niken Adisty; Yannick Wouters; Michel Kester; Hanny Fredrix; Joop H Jansen; Bert van der Reijden; J H Frederik Falkenburg; Theo de Witte; Frank Preijers; Ton Schattenberg; Ton Feuth; Nicole M Blijlevens; Nicolaas Schaap; Harry Dolstra
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-27       Impact factor: 5.742

8.  Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.

Authors:  Sarah Nicholls; Karen P Piper; Fiyaz Mohammed; Timothy R Dafforn; Stefan Tenzer; Mahboob Salim; Premini Mahendra; Charles Craddock; Peter van Endert; Hansjörg Schild; Mark Cobbold; Victor H Engelhard; Paul A H Moss; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

Review 9.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

10.  C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.

Authors:  Scott S Tykodi; Nobuharu Fujii; Nathalie Vigneron; Sharon M Lu; Jeffrey K Mito; Maureen X Miranda; Jeffrey Chou; Lilien N Voong; John A Thompson; Brenda M Sandmaier; Peter Cresswell; Benoît Van den Eynde; Stanley R Riddell; Edus H Warren
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.